EMI56 |
| Katalog-Nr.GC62420 |
EMI56, das Derivat von EMI1, zeigt eine grÖßere Potenz gegenÜber mutiertem EGFR als EMI1. EMI56 hemmt EGFR-Dreifachmutanten.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2414374-41-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
EMI56, the derivative of EMI1, displays greater potency toward mutant EGFR than EMI1. EMI56 inhibits EGFR triple mutants[1].
EMI56 inhibits EGFR ex19del/T790M/C797S and EGFR L858R/T790M/C797S. EMI56 can be used in the research of mutant EGFR-associated, drug-resistant non-small-cell lung cancer (NSCLC)[1].EMI56 (10, 15, 20 μM; 2 h of treatment) strongly inhibits total EGFR levels, activation and downstream signaling in PC9 EGFR ex19del/T790M/C797S cells[1].
[1]. Punit Saraon, et al. A Drug Discovery Platform to Identify Compounds That Inhibit EGFR Triple Mutants.Nat Chem Biol. 2020 May;16(5):577-586.
Average Rating: 5 (Based on Reviews and 27 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *